Skip to content
10-K

Annual Report

Pear Therapeutics, Inc.

0001835567-23-000018

← back to feed
Filed
Mar 31, 2023 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2022 · Mar 30, 2023 142.74M sh
Shares Diluted FY 2022 · Dec 31, 2022 138.71M sh
Shares Diluted FY 2022 · Dec 31, 2021 113.33M sh
Capex FY 2022 · Dec 31, 2022 $3.47M
Capex FY 2022 · Dec 31, 2021 $3.28M
Operating Cash Flow FY 2022 · Dec 31, 2022 −$113.9M
Operating Cash Flow FY 2022 · Dec 31, 2021 −$109.04M
Long Term Debt FY 2022 · Dec 31, 2022 $0
Short Term Debt FY 2022 · Dec 31, 2022 $27.45M
Short Term Debt FY 2022 · Dec 31, 2021 $26.99M
Short Term Investments FY 2022 · Dec 31, 2022 $10.97M
Short Term Investments FY 2022 · Dec 31, 2021 $5M
Cash And Equivalents FY 2022 · Dec 31, 2022 $48.3M
Cash And Equivalents FY 2022 · Dec 31, 2021 $169.57M
Stockholders Equity FY 2022 · Dec 31, 2022 $30.59M
Stockholders Equity FY 2022 · Dec 31, 2021 $90.43M
Stockholders Equity FY 2022 · Dec 31, 2020 $87.12M
Current Liabilities FY 2022 · Dec 31, 2022 $49.44M
Current Liabilities FY 2022 · Dec 31, 2021 $47.17M
Total Liabilities FY 2022 · Dec 31, 2022 $64.54M
Total Liabilities FY 2022 · Dec 31, 2021 $106.73M
Current Assets FY 2022 · Dec 31, 2022 $72.96M
Current Assets FY 2022 · Dec 31, 2021 $185.24M
Total Assets FY 2022 · Dec 31, 2022 $95.13M
Total Assets FY 2022 · Dec 31, 2021 $197.16M
Eps Diluted FY 2022 · Dec 31, 2022 −$0.54
Eps Diluted FY 2022 · Dec 31, 2021 −$0.57
Eps Basic FY 2022 · Dec 31, 2022 −$0.54
Eps Basic FY 2022 · Dec 31, 2021 −$0.57
Sga Expense FY 2022 · Dec 31, 2022 $79.55M
Sga Expense FY 2022 · Dec 31, 2021 $67.62M
Rd Expense FY 2022 · Dec 31, 2022 $48.31M
Rd Expense FY 2022 · Dec 31, 2021 $37.04M
Net Income FY 2022 · Dec 31, 2022 −$75.49M
Net Income FY 2022 · Dec 31, 2021 −$65.14M
Operating Income FY 2022 · Dec 31, 2022 −$123.35M
Operating Income FY 2022 · Dec 31, 2021 −$105.69M
Cost Of Revenue FY 2022 · Dec 31, 2022 $8.18M
Cost Of Revenue FY 2022 · Dec 31, 2021 $5.23M
Revenue FY 2022 · Dec 31, 2022 $12.69M
Revenue FY 2022 · Dec 31, 2021 $4.21M